NASDAQ Framework: Amneal Pharmaceuticals Inc.

Global pharmaceutical company offering generics, injectables, biosimilars 1 2.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company headquartered in Bridgewater, NJ. The company operates through three segments: Generics, Specialty, and AvKARE, offering a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. Amneal is rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies, delivering more affordable access to essential medicines through its robust U.S. generics business, a growing branded business, and deepening portfolios in institutional injectables, biosimilars, and select international markets 3 4 5.

3: Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. View Source4: About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com. View Source5: Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, we’re rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. View Source

UNKNOWN

The provided facts do not specify whether Amneal Pharmaceuticals Inc. is still led by its founders or if the founders are heavily involved in the company's current operations.

MEDIUM RISK

Amneal Pharmaceuticals Inc. has shown significant revenue growth and a robust portfolio expansion, particularly in injectables and biosimilars 6 7 8. However, the company reported a loss per share of US$0.30 in Q1 2024, which is a significant increase from the US$0.046 loss in Q1 2023 9. Additionally, insider sales by company directors indicate potential concerns about stock performance 10 11. These factors suggest that while the company is growing, it faces financial challenges that place it at a medium risk level.

6: Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. View Source7: Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies View Source8: Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar View Source9: Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) View Source10: Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX) View Source11: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 63.99 percent of Amneal Pharmaceuticals Inc shares are owned by insiders, and 27.21 percent are held by financial institutions. Autor Deborah M., the Director at Amneal Pharmaceuticals Inc (AMRX) has sold 23,447 shares of firm on May 17 ’24 at a price of $6.73 against the total amount of $0.16 million. In another inside trade, Autor Deborah M., Director of Amneal Pharmaceuticals Inc (NASDAQ:AMRX) sold 14,553 shares of the firm on May 16 ’24 for a total worth of $98378.0 at a price of $6.76. An inside trade which took place on Aug 11 ’23, Executive Vice President of Amneal Pharmaceuticals Inc BOYER ANDREW S sold 29,302 shares of firm against total price of $0.12 million at the cost of $4.13 per share. View Source

YES

Amneal Pharmaceuticals Inc. is launching new product offerings. They recently announced the launch of FOCINVEZ™, a ready-to-use injectable version of fosaprepitant 12 13.

12: Amneal to Report Second Quarter 2024 Results on August 9, 2024 BRIDGEWATER, N.J., July 11, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. Business Wire • 10 days ago AMRX Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant BRIDGEWATER, N.J., July 09, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. Business Wire • 12 days ago AMRX Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) PISCATAWAY, N.J., July 01, 2024--Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States. Business Wire • 20 days ago AMRX Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar BRIDGEWATER, N.J., July 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the addition of omalizumab, referencing XOLAIR®, to its biosimilar pipeline. Business Wire • 20 days ago AMRX Amneal Releases 2023 Environmental, Social and Governance Report BRIDGEWATER, N.J., June 28, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-profit Business Wire • 23 days ago AMRX Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies BRIDGEWATER, N.J., June 05, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company’s total number of commercial injectable products available for the U.S. institutional market to over 40. Business Wire • last month AMRX Amneal to Participate at Upcoming Investor Conference BRIDGEWATER, N.J., May 22, 2024--Amneal to Participate at Upcoming Investor Conference Business Wire • last month AMRX Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California BRIDGEWATER, N.J., May 22, 2024--Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California Business Wire • last month AMRX Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX) On May 17, 2024, Deborah Autor, Director at Amneal Pharmaceuticals Inc (NASDAQ:AMRX), executed a sale of 38,000 shares of the company. GuruFocus.com • last month AMRX Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) Amneal Pharmaceuticals ( NASDAQ:AMRX ) First Quarter 2024 Results Key Financial Results Revenue: US$659.2m (up 18% from... Simply Wall St. • 2 months ago AMRX Amneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... Amneal Pharmaceuticals reports significant revenue and EBITDA growth in Q1 2024, driven by new product launches and strong market performance. GuruFocus.com • 2 months ago AMRX Amneal Reports First Quarter 2024 Financial Results BRIDGEWATER, N.J., May 03, 2024--AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Business Wire • 2 months ago AMRX Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose BRIDGEWATER, N.J., April 24, 2024--Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Business Wire • 2 months ago AMRX Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine BRIDGEWATER, N.J., April 16, 2024--Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine Business Wire • 3 months ago AMRX Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a... Simply Wall St. • 3 months ago AMRX Amneal to Report First Quarter 2024 Results on May 3, 2024 BRIDGEWATER, N.J., April 10, 2024--Amneal to Report First Quarter 2024 Results on May 3, 2024 Business Wire • 3 months ago AMRX Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 BRIDGEWATER, N.J., March 28, 2024--Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 Business Wire • 3 months ago AMRX Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension BRIDGEWATER, N.J., March 25, 2024--Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Business Wire • 3 months ago AMRX Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results Despite Revenue Growth, Company Faces GAAP Net Loss and Provides 2024 Guidance GuruFocus.com • 4 months ago AMRX Amneal Reports Fourth Quarter and Full Year 2023 Financial Results BRIDGEWATER, N.J., March 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the fourth quarter and full year ended December 31, 2023. Business Wire • 4 months ago AMRX View Source13: Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant View Source

Amneal Pharmaceuticals Inc. is strategically expanding its product portfolio and market presence from 2024 through 2026 by focusing on several key areas. The company is enhancing its injectables portfolio, having added six new therapies in the second quarter of 2024, bringing its total to over 40 products 14. Additionally, Amneal is growing its biosimilars pipeline, including the recent addition of an omalizumab biosimilar 15. The company is also advancing its branded business with the launch of innovative products like FOCINVEZ™, a ready-to-use injectable 16. These efforts are complemented by a commitment to sustainability and human capital management, as highlighted in their 2023 Environmental, Social, and Governance (ESG) report 17.

14: Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies View Source15: Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar View Source16: Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant View Source17: Amneal Releases 2023 Environmental, Social and Governance Report View Source

Sources

1: Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. View Source2: About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com. View Source3: Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. View Source4: About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com. View Source5: Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, we’re rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. View Source6: Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. View Source7: Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies View Source8: Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar View Source9: Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) View Source10: Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX) View Source11: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 63.99 percent of Amneal Pharmaceuticals Inc shares are owned by insiders, and 27.21 percent are held by financial institutions. Autor Deborah M., the Director at Amneal Pharmaceuticals Inc (AMRX) has sold 23,447 shares of firm on May 17 ’24 at a price of $6.73 against the total amount of $0.16 million. In another inside trade, Autor Deborah M., Director of Amneal Pharmaceuticals Inc (NASDAQ:AMRX) sold 14,553 shares of the firm on May 16 ’24 for a total worth of $98378.0 at a price of $6.76. An inside trade which took place on Aug 11 ’23, Executive Vice President of Amneal Pharmaceuticals Inc BOYER ANDREW S sold 29,302 shares of firm against total price of $0.12 million at the cost of $4.13 per share. View Source12: Amneal to Report Second Quarter 2024 Results on August 9, 2024 BRIDGEWATER, N.J., July 11, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. Business Wire • 10 days ago AMRX Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant BRIDGEWATER, N.J., July 09, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. Business Wire • 12 days ago AMRX Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) PISCATAWAY, N.J., July 01, 2024--Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States. Business Wire • 20 days ago AMRX Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar BRIDGEWATER, N.J., July 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the addition of omalizumab, referencing XOLAIR®, to its biosimilar pipeline. Business Wire • 20 days ago AMRX Amneal Releases 2023 Environmental, Social and Governance Report BRIDGEWATER, N.J., June 28, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-profit Business Wire • 23 days ago AMRX Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies BRIDGEWATER, N.J., June 05, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company’s total number of commercial injectable products available for the U.S. institutional market to over 40. Business Wire • last month AMRX Amneal to Participate at Upcoming Investor Conference BRIDGEWATER, N.J., May 22, 2024--Amneal to Participate at Upcoming Investor Conference Business Wire • last month AMRX Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California BRIDGEWATER, N.J., May 22, 2024--Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California Business Wire • last month AMRX Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX) On May 17, 2024, Deborah Autor, Director at Amneal Pharmaceuticals Inc (NASDAQ:AMRX), executed a sale of 38,000 shares of the company. GuruFocus.com • last month AMRX Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) Amneal Pharmaceuticals ( NASDAQ:AMRX ) First Quarter 2024 Results Key Financial Results Revenue: US$659.2m (up 18% from... Simply Wall St. • 2 months ago AMRX Amneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... Amneal Pharmaceuticals reports significant revenue and EBITDA growth in Q1 2024, driven by new product launches and strong market performance. GuruFocus.com • 2 months ago AMRX Amneal Reports First Quarter 2024 Financial Results BRIDGEWATER, N.J., May 03, 2024--AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Business Wire • 2 months ago AMRX Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose BRIDGEWATER, N.J., April 24, 2024--Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Business Wire • 2 months ago AMRX Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine BRIDGEWATER, N.J., April 16, 2024--Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine Business Wire • 3 months ago AMRX Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a... Simply Wall St. • 3 months ago AMRX Amneal to Report First Quarter 2024 Results on May 3, 2024 BRIDGEWATER, N.J., April 10, 2024--Amneal to Report First Quarter 2024 Results on May 3, 2024 Business Wire • 3 months ago AMRX Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 BRIDGEWATER, N.J., March 28, 2024--Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 Business Wire • 3 months ago AMRX Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension BRIDGEWATER, N.J., March 25, 2024--Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Business Wire • 3 months ago AMRX Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results Despite Revenue Growth, Company Faces GAAP Net Loss and Provides 2024 Guidance GuruFocus.com • 4 months ago AMRX Amneal Reports Fourth Quarter and Full Year 2023 Financial Results BRIDGEWATER, N.J., March 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the fourth quarter and full year ended December 31, 2023. Business Wire • 4 months ago AMRX View Source13: Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant View Source14: Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies View Source15: Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar View Source16: Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant View Source17: Amneal Releases 2023 Environmental, Social and Governance Report View Source